Changes in tumor metabolism as readout for mammalian target of rapamycin kinase inhibition by rapamycin in glioblastoma

Clinical Cancer Research

Volumn 14, Issue 11, 2008, Pages 3416-3426

  Wei, Liu Hua ^a   Su, Helen ^a   Hildebrandt, Isabel J ^a   Phelps, Michael E ^a   Czernin, Johannes ^a   Weber, Wolfgang A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3' FLUOROTHYMIDINE F 18; AMINO ACID; FLUORODEOXYGLUCOSE F 18; GLUCOSE; HEXOKINASE; MAMMALIAN TARGET OF RAPAMYCIN; RAPAMYCIN; THYMIDINE; THYMIDINE KINASE; TYROSINE; ANTINEOPLASTIC ANTIBIOTIC; DIAGNOSTIC AGENT; FLUORINE; PROTEIN KINASE; THYMIDINE KINASE 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; DRUG METABOLISM; DRUG MONITORING; DRUG UPTAKE; ENZYME INHIBITION; GLIOBLASTOMA; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCID MOUSE; TREATMENT RESPONSE; ANIMAL; CELL PROLIFERATION; DRUG EFFECT; METABOLISM; SCINTISCANNING; TUMOR CELL LINE;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; CELL LINE, TUMOR; CELL PROLIFERATION; FLUORINE RADIOISOTOPES; FLUORODEOXYGLUCOSE F18; GLIOBLASTOMA; GLUCOSE; HUMANS; MICE; POSITRON-EMISSION TOMOGRAPHY; PROTEIN KINASES; SIROLIMUS; THYMIDINE; THYMIDINE KINASE; TYROSINE;

EID: 50349083186     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-1824     Document Type: Article

References (50)

1. Mitchell P, Ellison DW, Mendelow AD. Surgery for malignant gliomas: mechanistic reasoning and slippery statistics. Lancet Neurol 2005;4:413-22.
2. Maher EA, Furnari FB, Bachoo RM, et al. Malignant glioma: genetics and biology of a grave matter. Genes Dev 2001;15:1311-33.
3. Abraham RT, Gibbons JJ. The mammalian target of rapamycin signaling pathway: twists and turns in the road to cancer therapy. Clin Cancer Res 2007;13:3109-14.
4. Gingras AC, Gygi SP, Raught B, et al. Regulation of 4E-BP1 phosphorylation: a novel two-step mechanism. Genes Dev 1999;13:1422-37.
5. Huang S, Houghton PJ. Inhibitors of mammalian target of rapamycin as novel antitumor agents: from bench to clinic. Curr Opin Investig Drugs 2002;3:295-304.
6. Yatscoff RW, LeGatt DF, Kneteman NM. Therapeutic monitoring of rapamycin: a new immunosuppressive drug. Ther Drug Monit 1993;15:478-82.
7. Faivre S, Kroemer G, Raymond E. Current development of mTOR inhibitors as anticancer agents. Nat Rev Drug Discov 2006;5:671-88.
8. Doherty L, Gigas DC, Kesari S, et al. Pilot study of the combination of EGFR and mTOR inhibitors in recurrent malignant gliomas. Neurology 2006;67:156-8.
9. Reardon DA, Quinn JA, Vredenburgh JJ, et al. Phase 1 trial of gefitinib plus sirolimus in adults with recurrent malignant glioma. Clin Cancer Res 2006;12:860-8.
10. Galanis E, Buckner JC, Maurer MJ, et al. Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study. J Clin Oncol 2005;23:5294-304.
11. Sharma S, Guthrie PH, Chan SS, Haq S, Taegtmeyer H. Glucose phosphorylation is required for insulin-dependent mTOR signalling in the heart. Cardiovasc Res 2007.
12. Fuchs BC, Finger R, Onan MC, Bode BP. ASCT2 silencing regulates mammalian target-of-rapamycin growth and survival signaling in human hepatoma cells. Am J Physiol Cell Physiol 2007.
13. Kimball SR. Jefferson LS. Signaling pathways and molecular mechanisms through which branched-chain amino acids mediate translational control of protein synthesis. J Nutr 2006;136:227-31S.
14. Raught B, Gingras AC, Sonenberg N. The target of rapamycin (TOR) proteins. Proc Natl Acad Sci U S A 2001;98:7037-44.
15. Vignot S, Faivre S, Aguirre D. Raymond E. mTOR-targeted therapy of cancer with rapamycin derivatives Ann Oncol 2005;16:525-37.
16. Boffa DJ, Luan F, Thomas D, et al. Rapamycin inhibits the growth and metastatic progression of non-small cell lung cancer. Clin Cancer Res 2004;10:293-300.
17. Herholz K, Coope D, Jackson A. Metabolic and molecular imaging in neuro-oncology. Lancet Neurol 2007;6:711-24.
18. Shields AF, Grierson JR, Dohmen BM, et al. Imaging proliferation in vivo with [F-18] FLTand positron emission tomography. Nat Med 1998;4:1334-6.
19. Schwartz JL,Tamura Y, Jordan R, Grierson JR. Krohn KA, Monitoring tumor cell proliferation by targeting DNA synthetic processes with thymidine and thymidine analogs. J Nucl Med 2003;44:2027-32.
20. Ishii N, Maier D, Merlo A, et al. Frequent co-alterations of TP53, p16/CDKN2A, p14ARF, PTEN tumor suppressor genes in human glioma cell lines. Brain Pathol 1999;9:469-79.
21. Su H, Bodenstein C, Dumont RA, et al. Monitoring tumor glucose utilization by positron emission tomography for the prediction of treatment response to epidermal growth factor receptor kinase inhibitors. Clin Cancer Res 2006;12:5659-67.
22. Aloj L, Caraco C, Jagoda E, Eckelman WC, Neumann RD. Glut-1 and hexokinase expression: relationship with 2-fluoro-2-deoxy-D-glucose uptake in A431 and T47D cells in culture. Cancer Res 1999;59:4709-14.
23. Sasajima T, Miyagawa T, Oku T, Gelovani JG, Finn R, Blasberg R. Proliferation-dependent changes in amino acid transport and glucose metabolism in glioma cell lines. Eur J Nucl Med Mol Imaging 2004;31:1244-56.
24. Robey RB, Raval BJ, Ma J, Santos AV. Thrombin is a novel regulator of hexokinase activity in mesangial cells Kidney Int 2000;57:2308-18.
25. Hale DA, Gottschalk R, Fukuzaki T, Wood ML. Maki T, Monaco AP. Superiority of sirolimus (rapamycin) over cyclosporine in augmenting allograft and xenograft survival in mice treated with antilymphocyte serum and donor-specific bone marrow. Transplantation 1997;63:359-64.
26. 26.Tai YC, Ruangma A, Rowland D, et al. Performance evaluation of the microPET focus: a third-generation microPET scanner dedicated to animal imaging. J Nucl Med 2005;46:455-63.
27. Fueger BJ, Czernin J, Hildebrandt I, et al. Impact of animal handling on the results of 18F-FDG PET studies in mice. J Nucl Med 2006;47:999-1006.
28. Chow P, Stout D, Komisopoulou E, Chatziioannou A. A method of image registration for small animal, multi-modality imaging. Phys Med Bil 2006:51:379-90.
29. Loening AM, Gambhir SS. AMIDE: a free software tool for multimodality medical image analysis. Mol Imaging 2003;2:131-7.
30. 18F-fluorothymidine PET J Nucl Med 2005;46:114-20.
31. Munch-Petersen B, Cloos L, Jensen HK, Tyrsted G. Human thymidine kinase 1. Regulation in normal and malignant cells. Adv Enzyme Regul 1995;35:69-89.
32. Lahoutte T, Caveliers V, Camargo SM, et al. SPECT and PET amino acid tracer influx via system L (h4F2hc-hLAT1) and its transstimulation. J Nucl Med 2004;45:1591-6.
33. Bhaskar PT, Hay N. The two TORCs and Akt. Dev Cell 2007;12:487-502.
34. Majumder PK, Febbo PG, Bikoff R, et al. mTOR inhibition reverses Akt-dependent prostate intraepithe lial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. Nat Med 2004;10:594-601.
35. Thomas GV, Tran C, Mellinghoff IK, et al. Hypoxia-inducible fador determines sensitivity to inhibitors of mTOR in kidney cancer. Nat Med 2006;12:122-7.
36. Macheda ML, Rogers S, Best JD. Molecular and cellular regulation of glucose transporter (GLUT) proteins in cancer. J Cell Physiol 2005;202:654-62.
37. Kim JW, Dang CV Multifaceted roles of glycolytic enzymes. Trends Biochem Sci 2005;30 142-50.
38. Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon a, or both for advanced renal-cell carcinoma. N Engl J Med 2007;356:2271-81.
39. 18F-FLT PET: comparison with 18F-FDG. J Nucl Med 2005;46:945-52.
40. Taschereau R. Chow PL. Chatziioannou AF. Monte Carlo simulations of dose from microCT imaging procedures in a realistic mouse phantom. Med Phys 2006;33:216-24.
41. Taschereau R, Chatziioannou AF. Monte Carlo simulations of absorbed dose in a mouse phantom from 18-fluorine compounds. Med Phys 2007;34:1026-36.
42. Kanai Y. Segawa H, Miyamoto K, Uchino H.Takeda E, Endou H. Expression cloning and characterization of a transporter for large neutral amino acids activated by the heavy chain of 4F2 antigen (CD98) J Biol Chem 1998;273:23629-32.
43. Sang J, Lim YP, Panzica M. Finch P, Thompson NL TA1, a highly conserved oncofetal complementary DNA from rat hepatoma, encodes an integral membrane protein associated with liver development, carcinogenesis, and cell activation. Cancer Res 1995;55:1152-9.
44. Fuchs BC, Bode BP. Amino acid transporters ASCT2 and LAT1 in cancer: partners in crime? Semin Cancer Biol 2005;15:254-66.
45. Edinger AL, Thompson CB. Akt maintains cell size and survival by increasing mTOR-dependent nutrient uptake. Mol Biol Cell 2002;13:2276-88.
46. Edinger AL. Linardic CM, Chiang GG, Thompson CB, Abraham RT Differential effects of rapamycin on mammalian target of rapamycin signaling functions in mammalian cells. Cancer Res 2003;63:8451-60.
47. Neshat MS, Mellinghoff IK, Tran C, et al. Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc Natl Acad Sci U S A 2001;98:10314-9.
48. Hosoi H. Dilling MB, Liu LN, et al. Studies on the mechanism of resistance to rapamycin in human cancer cells. Mol Pharmacol 1998;54:815-24.
49. Duran I, Kortmansky J, Singh D, et al. A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas Br J Cancer 2006;95:1148-54.
50. Peralba JM. DeGtaffenried L, Fnedrichs W, et al. Pharmacodynamic evaluation of CCI-779, an inhibitor of mTOR, in cancer patients Clin Cancer Res 2003;9:2887-92.